Our Focus Understanding complex relationships in gene regulation
Epigenetic markers, including modifications of DNA, RNA and histone proteins, work in concert to control how the genetic code is used in health and disease. Unlike current methods that detect single modifications one at a time, our technology accurately detects and locates many epigenetic markers simultaneously.
Reading the Epitranscriptome
The epitranscriptome encompasses all naturally occurring chemical modifications of RNA. While our understanding of the epitranscriptome is still incomplete, there is ample evidence for a critical role of RNA modifications, including vital functions in cancer progression, drug resistance, cell differentiation and viral infection.
Our mission is to create innovative technology for reading of the epitranscriptome.
New Drug Targets
RNA modification writers, erasers and readers are becoming important cancer drug targets. Drugs targeting histone modification writers and erasers are already in the clinic.
Therapeutic RNA editing is gaining traction, because unlike CRISPR and prime editing of DNA, editing of RNA does not permanently alter a cell and its progeny and may have a lower risk of long-term side effects.
Basic and Clinical Research
Identifying and locating RNA modifications will improve the understanding of systems biology and disease mechanisms, delivering new diagnostics and better treatment regimes.
With our assay you will be able to study the RNA modifications that are most relevant to your biological question. Obtaining the identity and location of multiple RNA modifications from the same experiment saves hands-on time and reduces variability.
Our assay provides the RNA modification landscape and RNA expression profile in a unified approach, enabling correlative data analysis at a new scale.
Some RNA modifications are known to be dysregulated in disease. To unlock their full potential, accurately quantitating their occurrence is indispensable. Our assay contains normalization controls to provide the relative fraction of modified and unmodified RNA for a given transcript.
The interpretation of genomics data tends to be complex, time consuming and highly customized by the end user. To get the most of our new data type, we are developing a proprietary analysis pipeline that is accessible via cloud or as desktop application.
Partnerships for Early Access
Our experienced team can provide tailored solutions and end-to-end analyses for your research needs. We work with pharmaceuticals, diagnostics, agricultural sciences, and other sectors to bring bespoke solutions to complex problems.
Gudrun Stengel, PhD
CEO & Co-Founder
As the leader of Alida Biosciences, Gudrun brings over a decade of genomics product development experience, from pioneering genomic analysis of tumor tissue at Affymetrix, to leading technical teams at Illumina for the NovaSeq™ platform, which is the highest output and quality DNA sequencer on the global market. Equipped with an in-depth understanding of the product development process, Gudrun ventured out into the VC-backed startup world. She joined Encodia, a proteomics company that uses DNA barcoding to reverse translate primary amino acid sequence into DNA sequence, where she developed fundamental technology to secure series B funding. Before Gudrun founded Alida Biosciences in fall 2021, she developed clustering and SBS reagents for Element Bio’s AVITI™ sequencing platform at Element Biosciences.
Gudrun was a postdoctoral researcher at the Scripps Research Institute and the University of Colorado Boulder. Gudrun received her Ph.D. in Biophysical Chemistry at the Max Planck Institute in Germany. Throughout her academic career she published more than 20 articles in peer-reviewed journal.
Byron Purse, PhD
As co-founder of Alida Biosciences, Byron manages chemistry projects and plays a key role in creating the patent portfolio and securing federal startup funding, which has translated into three NIH Small Business Innovation Awards.
Byron is a Professor of Organic Chemistry at San Diego State University, where he leads an NSF-funded research team focused on chemical biology of nucleic acids. Byron has over 35 publications in top-ranked chemistry journals and as a project leader in academia has raised several million dollars in federal research funding. Byron received his Ph.D. in Organic Chemistry at the Scripps Research Institute.
Timothy Burcham, PhD
Senior Vice President, Informatics
Tim has over two decades of experience developing and commercializing solutions for the biotech and research industries. His career focus has been developing new DNA sequencing platforms, from the early days at Applied Biosystems with the first automated Sanger sequencers, to high throughput next generation sequencing, including the first commercial NGS service at Lynx Therapeutics working with Sydney Brenner. While at companies such as diaDexus and Sequenom, he worked on the applications of sequencing and NGS developing, getting FDA approval for, and commercialization of several diagnostics tests and systems. Most recently he contributed to the development of a next gen proteomics system at Encodia, Inc.
Tim has a Ph.D. in Biochemistry and Biophysics from UC Davis and postdoc at Stanford University.
Andrew Price, PhD
Vice President, R&D
Andrew brings 10 years’ experience scaling and successfully developing commercial solutions at biotech startups having directed R&D teams at all phases of product development. At previous innovative genomics companies including 10X Genomics and Element Biosciences, he has contributed to the launch of ground-breaking products such as Chromium WGS, Chromium 3’ Single Cell Gene Expression and the AVITI™ sequencing platform.
He completed his Ph.D. in Chemical Engineering at the University of Colorado – Boulder with continuing postdoctoral training in nanoscience and macromolecular chemistry at The University of Melbourne and Sandia National Laboratories.
Zachary Miles, PhD
Director of Protein Engineering
Zach leads the Protein Engineering Department at Alida Bio with extensive experience translating protein and enzyme design concepts into next-generation biological components for diverse industries. He previously worked at BASF Enzymes in San Diego, engineering enzymes as additives for various industrial and commercial purposes, such as personal care chemicals and biofuel production. Prior to his current role, he led the Protein Engineering group at Encodia where he was responsible for development of the biological binding reagents in their single-molecule protein sequencing technology.
Zach completed his Ph.D. at the University of Arizona where his doctoral work focused on the discovery and biochemical characterization of enzymes involved in the biosynthesis of a ubiquitous tRNA modification.
Careers We're always looking for new talent.
As an early stage company, we offer a vibrant, diverse, and creative environment with excellent opportunities for career growth.
Located in the heart of the San Diego biotech community, we provide competitive salaries and benefits, such as an employee stock plan, health coverage, 401K plan, work out facilities, PTO, sick leave, and paid holidays.
Latest Articles Company News
Alida Bio has completed its move to a new space in San Diego’s Sova Science District.
Alida Bio scores a third SBIR grant, “Positional Marking of RNA Modifications”
A second SBIR grant is awarded to Alida Bio, “Rapid NGS Method for Mapping of the Epitranscriptome”
The Illumina Alumni network publishes an interview with Alida Bio’s CEO
Alida Bio receives its first Small Business Innovation Award (SBIR) by the National Institute of Health
Contact Us Get In Touch
Please send us a message to discuss partnership opportunities and career openings.
You can find us here:
Like what you see? Send us a message to discuss partnership opportunities and career openings.